Hyperfractionated reirradiation with cetuximab for recurrent head and neck cancer: The GORTEC 2008-01 multicentric phase II study.

Mathilde Saint-Ghislain, Yungan Tao, Marc Alfonsi, Pierre Boisselier, Muriel Garcia-Ramirez, Claude Tuchais, Philippe Maingon, Christian Sire, Ali Hasbini, Marie Saliou, Cedrik Lafond, Hao Qiu, Sébastien Guihard, Pascal Garaud, marie-Helene Calais, Juliette Thariat, Laurent Martin, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6034)

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

Yungan Tao, Anne Auperin, Xu Shan Sun, Christian Sire, Laurent Martin, G Bera, Alexandre Coutte, Jessica Miroir, Cedrik Lafond, Natacha Colin-Batailhou, Aline Maillard, Laurent Gibel, Cécile Michel, Joel Guigay, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6076)

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Shan Sun, Christian Sire, Yungan Tao, Laurent Martin, Marc Alfonsi, Jean Briac Prevost, Michel Rives, Cedrik Lafond, Jean-Marc Tourani, Julian Biau, Lionnel Geoffrois, Alexandre Coutte, Xavier Liem, Elodie Vauleon, Franck Drouet, Jean-François Ramee, Gabriel Waksi, Laura Sinigaglia, Anne Auperin, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6018)